EAN Highlights - touchNEUROLOGY are the Official Virtual Congress Partner to the EAN
WBD 2020: EAN Interview with Prof. Elena Moro and Prof. Günther Deuschl
Video produced by and shared with kind authorisation of the European Academy of Neurology (EAN). On World Brain Day 2020, Professor Günther Deuschl, EAN Past President, gets interviewed by Professor Elena Moro, EAN Secretary General, about research and treatment on Parkinson’s disease.
WBD 2020: EAN Interview with Joke Jaarsma, Joe Condon and Veerle Aertsen
Video produced by and shared with kind authorisation of the European Academy of Neurology (EAN). On this World Brain Day, the European Federation of Neurological Associations (EFNA) president Joke Jaarsma is interviewing two patients with Parkinson’s disease (PD) on their views to improve clinical care in PD. Veerle Aertsen, vice-president of RaDiOrg, the Belgian Rare Diseases Organisation, […]
WBD 2020: EAN Interview with Prof. Günther Deuschl and Prof. Claudia Trenkwalder
Video produced by and shared with kind authorisation of the European Academy of Neurology (EAN). This World Brain Day, Professor Günther Deuschl, EAN Past President is talking to Professor Claudia Trenkwalder, President of the International Parkinson Disease and Movement Disorders Society about the burden of Parkinson´s Disease.
Sean Pittock, EAN 2020 – Phase 3 PREVENT Study Insights in Neuromyelitis Optica Spectrum Disorder
Sean Pittock (Mayo Clinic College of Medicine, Rochester, MN, USA) shared with us his expert insights from the phase 3 PREVENT study, a randomized controlled trial of eculizumab in AQP4 antibody-positive participants with neuromyelitis optica (ClinicalTrials.gov Identifier: NCT01892345), including a sub analysis he presented on eculizumab monotherapy. Questions 1. Could you give us an overview […]
Bengt Winblad, EAN 2020 – Swedish Geriatric Neurologist Perspective on COVID-19
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including his perspective on the COVID-19 pandemic as a Swedish geriatric neurologist. Question What are your thoughts on the COVID-19 pandemic as a Swedish geriatric neurologist? (0:05) Also see […]
Peter Goadsby, EAN 2020 – Visual Snow Syndrome
Delighted to interview our valued Editorial Board member Peter Goadsby (King’s College Hospital, London, UK), who shared his expert insights on visual snow syndrome and related updates presented at the 1st Virtual EAN Congress. Questions 1. What are the clinical features and spectrum of severity of visual snow syndrome, and how was it first identified? […]
Xavier Montalban, EAN 2020 – Long-term Phase II Outcomes of First Oral BTK Inhibitor in MS
Xavier Montalban (St Michael’s Hospital, University of Toronto, Toronto, Canada and Vall d’Hebron University Hospital, Barcelona, Spain) shares his expert insights on the rationale for the use of evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in the treatment of patients with relapsing multiple sclerosis (MS), as well as an overview of key efficacy and safety […]
Celia Oreja-Guevara, EAN 2020 – Regional Findings From The Phase 3 PREVENT Study in NMOSD
Great to have an opportunity to speak with Celia Oreja-Guevara (University Hospital San Carlos and University Complutense, Madrid, Spain) around the highlights of her presentation entitled: Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study (ClinicalTrials.gov Identifier: NCT01892345). Questions 1. What were […]
Bianca Weinstock-Guttman, EAN 2020 – CHORDS Study in RRMS With Suboptimal Prior Response to DMTs
Bianca Weinstock-Guttman (Jacobs School of Medicine and Biomedical Science, University of Buffalo, NY, USA) shares highlights of her presentation entitled: Effectiveness and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy: 2-year findings from CHORDS (ClinicalTrials.gov Identifier: NCT02637856). Questions 1. What are the potential advantages of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!